ArticleAnnals of hematology2019
Immunosuppressive therapy for aplastic anemia: a single-center experience from western India.
Article in Annals of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Febrile neutropenia in pediatric acquired aplastic anemia: a 20-year analysis of infections and mortality.Annals of hematology · 2026Article
- Correlation analysis of cyclosporine A trough concentration with hematological and biochemical parameters: a retrospective study in pediatric aplastic anemia.Frontiers in pediatrics · 2026Article
- Outcome of immunosuppressive therapy in pediatric patients with acquired aplastic anemia.Journal of family medicine and primary care · 2025Article
- Identification of molecular heterogeneity in telomere maintenance pathway of aplastic anemia.Molecular biology reports · 2025Article
- Outcomes after Immunosuppressive Therapy for Aplastic Anemia: A Single Centre Experience from Northern India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Response to Immunosuppressive Therapy in Aplastic Anemia-A Single Centre, Prospective Study of 158 Patients from a Tertiary Care Centre in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Comparable outcomes with low-dose and standard-dose horse anti-thymocyte globulin in the treatment of severe aplastic anemia.Blood research · 2024Article
- Combating bone marrow failure with polymer materials.Frontiers in immunology · 2024Review
- Idiopathic Aplastic anemia: Indian Perspective.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023Review
- Profile and Predictors of Infection Following Anti-thymocyte Globulin or Anti-lymphocyte Globulin with Cyclosporine in Aplastic Anemia.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023Article
- A Single-Centre Experience of First-Line Romiplostim and Immunosuppressive Therapy in Patients With Aplastic Anemia.Cureus · 2023Article
- Effect of Stanozolol combined with Cyclosporine A on aplastic anemia.American journal of translational research · 2023Article
- PRMT5 regulates epigenetic changes in suppressive Th1-like iTregs in response to IL-12 treatment.Frontiers in immunology · 2023Article
- A multicentre trial of intensive immunosuppressive therapy combined with umbilical cord blood for the treatment of severe aplastic anaemia.Annals of hematology · 2022Article
- [Reassessing the six months prognosis of patients with severe or very severe aplastic anemia without hematological responses at three months after immunosuppressive therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Response to Immunosuppressive Therapy in Acquired Aplastic Anaemia: Experience of a Tertiary Care Centre from Eastern India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2021Article
- Hemorrhagic manifestation in different etiologies of pancytopenia: A prospective, cross-sectional study.Journal of family medicine and primary care · 2021Article
- Response to Horse ATG (Thymogam, Bharat Serums and Vaccine, India) and Cyclosporine in Aplastic Anemia: A Single Centre, Retrospective Study of 60 Patients from Southern India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Article
- Aplastic Anemia: Non-COVID Casualties in the COVID-19 Era.Indian journal of palliative care · 2020Article
- Anti-thymocyte globulin in haematology: Recent developments.The Indian journal of medical research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine A (CsA) is the first-line therapy for acquired aplastic anemia (AA) in those not suitable for bone marrow transplant. Horse ATG (hATG) is preferred for this purpose, but its use is often impeded by shortages and costs. Being a rare disease, there is limited data on this therapy. This study aimed to evaluate this therapy in a large cohort of AA patients from western India. We retrospectively analyzed AA patients who received an indigenous preparation of hATG along with CsA as first-line treatment, between 2012 and 2015, at our center and evaluated the response, survival, and occurrence of adverse events. The response was further assessed separately for adults and children. During the period, 91 AA patients (4 non-severe, 57 severe and 30 very severe) were treated with IST. At 2 years, 23.5% adults and 39.1% children showed complete response and an overall of 68.1% cases became transfusion independent. More than half of the patients developed febrile neutropenia while roughly one sixth of the patients developed gum hypertrophy and/or hypertension. Two patients had clonal evolution. Mortality rate was calculated to be 31%; most common causes of death were infection and intracranial hemorrhage. The results of the study substantiate the effectiveness of IST in AA, using an inexpensive indigenous preparation of hATG along with CsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.